Categories
Tag: DLBCL
Assessing the Durability, Tolerability of Loncastuximab in R/R DLBCL
CASE A 73-year-old woman presented with fever, headaches, and 7-lb unintentional weight loss. Medical history: no family history of cancer, and hyperlipidemia that was well controlled with simvastatin. Physical exam: palpable bilateral cervical lymphadenopathy Laboratory results: lactate dehydrogenase, 265 U/L (280 U/L upper limit); Hemoglobulin, 10.8 g/dL; bilirubin, 1.3 mg/dL…
Use of CD32, CD44 and CD71 to differentiate follicular lymphoma and diffuse large B-cell lymphoma subtypes by flow cytometry
Many lymphomas can be immunophenotyped by flow cytometry (FCM), providing valuable diagnostic information.1 However, FCM cannot typically be used to distinguish follicular lymphoma (FL), diffuse large B-cell lymphoma, germinal centre type (DLBCL-GCB) and diffuse large B-cell lymphoma, non-germinal centre type (DLBCL-nGCB). To expand the utility of clinical FCM, we compared…
New strategy for safer CAR T cell therapy in lymphomas
Graphical Abstract. Credit: Cell Reports Medicine (2024). DOI: 10.1016/j.xcrm.2024.101421 In treating aggressive lymphomas and blood cancer (leukemia), chimeric antigen receptor T cells (CAR T cells) are increasingly being used. For this therapy, immune cells are taken from patients and programmed by means of genetic engineering to detect proteins in the…
ADC Therapeutics (ADCT) Rises 43% in a Month: Here’s Why
ADC Therapeutics ADCT is a commercial-stage biotech company focused on developing novel antibody-drug conjugates (ADC) to treat patients with hematologic malignancies and solid tumors. Currently, ADC Therapeutics has only one marketed drug in its portfolio, Zynlonta, which the FDA approves to treat relapsed or refractory (r/r) diffuse large B-cell lymphoma…
Study Highlights Treatment Patterns, Costs for DLBCL Not Treated With Stem Cell Transplant
New research highlights treatment patterns, health care resource utilization (HCRU), and costs associated with patients who have diffuse large B-cell lymphoma (DLBCL) who did not undergo stem cell transplantation in the second-line setting between 2009 and 2020. Of a 750-patient cohort, 86.8% received rituximab plus cyclophosphamide, doxorubicin, vincristine (Oncovin), and…
Prashant Mehta: My thoughts on developments in DLBCL management
Prashant Mehta, Senior Consultant and Assistant Professor in the Department of Medical Oncology/Hematology-oncology and Bone marrow transplantation at the Amrita Hospital, Faridabad, shared a thread on X/Twitter: “My thoughts on developments in Diffuse Large B Cell Lymphoma (DLBCL) management: Despite several combination studies with R-CHOP, in the last 20 years…
Patient Education and Monitoring in DLBCL Treatment
This is a video synopsis/summary of a Practice Pearls involving Zahra Mahmoudjafari, PharmD, MBA, BCOP, FHOPA; Robert Mancini, PharmD; and Amir Ali, PharmD, BCOP, FHOPA. In this segment, Mahmoudjafari interviews Mancini about the education and shared decision-making processes for patients receiving bispecific therapies in DLBCL. Mancini emphasizes the multidisciplinary approach…
A system review and meta-analysis
The microenvironment of diffuse large B-cell lymphoma (DLBCL) is composed of various components, including immune cells and immune checkpoints, some of which have been correlated with the prognosis of DLBCL, but their results remain controversial. Therefore, we conducted a systematic review and meta-analysis to investigate the association between the microenvironment…
Vincerx Pharma Announces Compelling Clinical Efficacy of Enitociclib in Combination with Venetoclax and Prednisone in Lymphoma
Vincerx Pharma, Inc. Investigators from the National Institutes of Health (NIH) report 2 partial responses (PR) in 3 peripheral T-cell lymphoma (PTCL) patients and 1 PR in 2 double-hit diffuse large b-cell lymphoma (DH-DLBCL) patients in ongoing dose-escalation trial of enitociclib in combination with venetoclax and prednisone Vincerx remains on…
Non-IG::MYC in diffuse large B-cell lymphoma confers variable genomic configurations and MYC transactivation potential
MYC translocation occurs in 8-14% of diffuse large B-cell lymphoma (DLBCL), and may concur with BCL2 and/or BCL6 translocation, known as double-hit (DH) or triple-hit (TH). DLBCL-MYC/BCL2-DH/TH are largely germinal centre B-cell like subtype, but show variable clinical outcome, with IG::MYC fusion significantly associated with inferior survival. While DLBCL-MYC/BCL6-DH are…
Cost and Benefit: Lisocabtagene Maraleucel is Cost Effective as Second-line Treatment for Lymphoma
Lisocabtagene maraleucel (liso-cel; Breyanzi®; Bristol-Myers Squibb), a CD19-directed genetically modified autologous T-cell immunotherapy, also known as chimeric antigen receptor (CAR) T-cell therapy, is a cost effective second line treatment for relapsed and refractory diffuse large B-cell lymphoma (r/r DLBCL). This conclusion is based on results from a study published in…
Identifying Prognostic Genes in Diffuse Large B-cell Lymphoma (DLBCL)
Diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin lymphoma, a cancer that starts in cells called lymphocytes, which are part of the body’s immune system. Its progression and prognosis vary significantly among patients, making it crucial to identify prognostic factors that can help predict patient outcomes…
New Geriatric Assessment Tools in DLBCL
Suchitra Sundaram, MD, reflects on a prospective study presented at ASH 2023 that investigated the use of geriatric assessment tools to better gauge which patients with non-Hodgkin lymphoma will experience treatment toxicities. In exploring the use of geriatric assessment tools to predict treatment toxicities, Dr Sundaram highlights the significance of…
SC-282 Shows Promising Results for DLBCL
The molecule SC-2882, developed by Scenic Biotech, has shown promising preclinical results for treating diffuse large B cell lymphoma (DLBCL), according to a recently published press release. Although R-CHOP chemotherapy is an effective treatment for most patients with DLBCL, a significant percentage of patients are resistant to treatment or relapse…
Ty’s Story: DLBCL – Lymphoma Australia
I was diagnosed with Diffuse Large B cell Lymphoma in early March of 2023. Three weeks before the diagnosis, I had a hospital procedure for thoracic outlet syndrome, which had caused blood clots in my right arm, resulting in a rib resection operation. Three weeks into my recovery, I was…
A Phase 3, Randomized, Open-Label Study to Evaluate Safety and Efficacy of Epcoritamab in Combination with R-CHOP Compared to R-CHOP in Subjects with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL) (EPCORE DLBCL-2)
Official Trial Title A Phase 3, Randomized, Open-Label Study to Evaluate Safety and Efficacy of Epcoritamab in Combination with R-CHOP Compared to R-CHOP in Subjects with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL) (EPCORE DLBCL-2) Study Description The University of Virginia seeks patients ages 18 and over with Newly Diagnosed…
How MRD Testing Can Help
MRD testing is incredibly valuable in informing clinical decision-making in the treatment of lymphoid malignancies, and its adoption by all oncologists is crucial in the era of precision medicine. During my 10 plus years of practicing medicine, I have seen the blood cancer treatment landscape transform, as the development of…
Diffuse Large B-Cell Lymphoma (DLBCL) Probe Panel by FISH – Laboratory Test Catalog
Test Name Alias DLBCL by FISH | Double Hit Lymphoma by FISH | Triple Hit Lymphoma by FISH | 9223 Interface Order Alias 11604 Clinical Information This probe panel detects specific structural chromosome abnormalities commonly associated with Diffuse Large B-cell Lymphoma. Routine chromosome analysis is performed on all diagnostic…
[Analysis of the feasibility and prognostic value of circulating tumor DNA monitoring in detecting gene mutations in patients with diffuse large B-cell lymphoma receiving chimeric antigen receptor T-cell therapy]
Objective: To explore the prognostic value of circulating tumor DNA (ctDNA) testing in patients with refractory/relapsed diffuse large B-cell lymphoma (R/R DLBCL) undergoing chimeric antigen receptor T-cell (CAR-T) therapy, and to guide the prevention and subsequent treatment of CAR-T-cell therapy failure. Methods: In this study, 48 patients with R/R DLBCL…
Advances in Anti-CD20 Therapies for Relapsed or Refractory Large B-Cell Lymphoma From ASH 2023
1. FDA D.I.S.C.O. Burst Edition: FDA approval of Epkinly (epcoritamab-bysp) for relapsed or refractory diffuse large B-cell lymphoma and high-grade B-cell lymphoma. News release. US Food and Drug Administration. June 21, 2023. Accessed December 6, 2023. www.fda.gov/drugs/resources-information-approved-drugs/fda-disco-burst-edition-fda-approval-epkinly-epcoritamab-bysp-relapsed-or-refractory-diffuse-large-b 2. FDA grants accelerated approval to glofitamab-gxbm for selected relapsed or refractory large B-cell…
Novel Combination Therapy Impresses With Safety/Efficacy in DLBCL
Christopher J. Melani, MD, assistant research physician in the Lymphoid Malignancies Branch at the Center for Cancer Research, National Cancer Institute, discusses updated data from the phase 1b/2 ViPOR trial (NCT03223610) of the combination of venetoclax (Venclexta), ibrutinib (Imbruvica), prednisone, obinutuzumab (Gazyva), and lenalidomide (Revlimid), in patients with diffuse large…
UChicago Medicine experts showcase blood cancer research at 65th ASH Annual Meeting
Faculty and trainees from the University of Chicago Medicine Comprehensive Cancer Center (UCCCC) joined the world’s largest hematology community to discuss the latest updates in blood cancers at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition held December 9-12, 2023 in San Diego and online. At the meeting,…
Variability in DNA methylation defines novel epigenetic subgroups of DLBCL associated with different clinical outcomes
Diffuse large B-cell lymphoma (DLBCL) is the most common aggressive form of non-Hodgkin lymphoma with variable biology and clinical behavior. The current classification does not fully explain the biological and clinical heterogeneity of DLBCLs. In this study, we carried out genomewide DNA methylation profiling of 140 DLBCL samples and 10…
ASH 2023: CAR T-Cell Therapy Safe, Effective for High-Risk DLBCL Patients
ASH 2023: CAR T-Cell Therapy Safe, Effective for High-Risk DLBCL Patients | PracticeUpdate …
Non-Hodgkin Lymphoma Market to Register Incremental Growth | AbbVie and Genmab, Roche, AstraZeneca, 4SC AG, Innate Pharma,Teva Pharma, Eli Lilly, and other companies are expected to change the Market scenario by 2032, forecasts DelveInsight.
DelveInsight’s “Non-Hodgkin lymphoma Market Insights, Epidemiology, and Market Forecast – 2032” report delivers an in-depth understanding of the NHL, historical and forecasted epidemiology as well as the Non-Hodgkin lymphoma market trends in the United States EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. {Delhi, India} To…
Clinical Challenges: Using Pola-R-CHP for Diffuse Large B-Cell Lymphoma
Earlier this year, the FDA approved a new frontline option for patients with diffuse large B-cell lymphoma (DLBCL): the antibody-drug conjugate polatuzumab vedotin (Polivy) in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone (pola-R-CHP). Combination chemotherapy involving rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) — and before that, CHOP alone —…
Therapeutic vaccines for aggressive B-cell lymphoma.
Therapeutic vaccines for aggressive B-cell lymphoma. Publication , Journal Article Xu-Monette, ZY; Young, KH Published in: Leuk Lymphoma Diffuse large B-cell lymphoma (DLBCL) is the most common aggressive B-cell lymphoma and highly heterogeneous disease. With the standard immunochemotherapy, anti-CD20 antibody rituximab (R-) plus CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) chemotherapy, 30-40%…
Outcomes of allogeneic hematopoietic stem cell transplantation for relapsed or refractory diffuse large B-cell lymphoma
Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002;346:235–242. Article CAS PubMed Google Scholar Philip T, Guglielmi C, Hagenbeek A, Somers R, Van der Lelie…
Golcadomide and Rituximab Combo in Patient with DLBCL
Date of Abstract presentation 11th December 2023 Indications Diffuse large B-cell lymphoma (DLBCL) Abstract Number 4496 Abstract type Poster Diffuse large B-cell lymphoma (DLBCL) stands as a swiftly progressing and aggressive ailment, representing the predominant type of non-Hodgkin lymphoma (NHL) and encompassing one-third of all diagnosed cases. Over two-thirds of…
EPKINLY Market Scenario for DLBCL Treatment through 2032
DUBLIN, Dec. 15, 2023 /PRNewswire/ — The “EPKINLY Drug Insight and Market Forecast – 2032” report has been added to ResearchAndMarkets.com‘s offering. Research_and_Markets_Logo The report offers detailed insights on EPKINLY and its market forecast for Diffuse Large B-cell lymphoma (DLBCL) has been made available, revealing crucial data intended for healthcare professionals and…
Research and Markets: MONJUVI (tafasitamab-cxix) Drug Insights and Market Forecasts, 2019-2022 and 2023-2032: Focus on 7MM – United States, Germany, France, Italy, Spain, United Kingdom, and Japan
The “MONJUVI Drug Insight and Market Forecast 2032” drug pipelines has been added to ResearchAndMarkets.com‘s offering. This “MONJUVI Drug Insight and Market Forecast 2032” report provides comprehensive insights about MONJUVI for Diffuse Large B-cell lymphoma (DLBCL) in the seven major markets. A detailed picture of the MONJUVI for DLBCL in…
Key Insights on Advances in DLBCL
Suchitra Sundaram, MD, breaks down the wealth of data presented at ASH 2023 and provides initial impressions of several key study results centering on new and encouraging treatments for diffuse large B-cell lymphoma. Starting with a landmark analysis of a phase 2 trial testing the efficacy of the bispecific antibody…
Clinical Challenges: CAR-T or Bispecifics in Relapsed/Refractory DLBCL
T-cell engaging therapeutic approaches have significantly changed the treatment paradigm for relapsed or refractory diffuse large B-cell lymphoma (DLBCL) in recent years. “They are, by a wide margin, the most impactful new therapies for all B-cell lymphomas, but especially DLBCL, in the last 40 years, if not ever,” said Joshua…
Final Analysis of the Phase 2 ELM-2 Study in Patients with DLBCL
Date of Abstract presentation 10th December 2023 Indications Diffuse Large B-cell lymphoma (DLBCL) Abstract Number 436 Abstract type Oral Odronextamab is an investigational CD20xCD3 bispecific antibody designed to bridge CD20 on cancer cells with CD3-expressing T cells to facilitate local T-cell activation and cancer-cell killing. The primary analysis of the…
Non-Hodgkin Lymphoma Pipeline and Clinical Trials Assessment 2023: FDA Approvals, Therapies and Key Companies involved by DelveInsight
PRESS RELEASE Published December 12, 2023 (Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Non-Hodgkin Lymphoma pipeline constitutes key companies continuously working towards developing Non-Hodgkin Lymphoma treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight. The Non-Hodgkin Lymphoma Pipeline report…
First-Line LTRA Plus CHOP Produces 100% Complete Response Rate in DLBCL
Upfront targeted therapy may reduce the need for chemotherapy in patients with diffuse large B-cell lymphoma (DLBCL), according to research presented at the ASH Annual Meeting 2023. Researchers found that first-line treatment with lenalidomide, tafasitamab, rituximab, and acalabrutinib (LTRA) seemed to reduce the need for cyclophosphamide, doxorubicin, vincristine, and prednisone…
From haemophilia to lymphoma, Roche presents new data at Ash 2023
Important new data on treatments in hematology, such as those for hemophilia A, diffuse large B-cell lymphoma and follicular lymphoma, were presented by Roche at the 65th meeting of the American Society of Hematology (Ash), in San Diego on 9 to 12 December. Data which – as we read in…
Tafasitamab Quadruplet Determined Safe, Feasible in Newly Diagnosed DLBCL
Lymphoma cells: © Dr_Microbe – stock.adobe.com A targeted combination regimen of lenalidomide (Revlimid), tafasitamab-cxix (Monjuvi), rituximab (Rituxan), and acalabrutinib (LTRA) seemed to be safe and effective in the first line as treatment for patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL), with the addition of cyclophosphamide, doxorubicin, vincristine, and…
Tafasitamab Quadruplet Appears Safe, Feasible in Newly Diagnosed DLBCL
This study inspired investigators to ask whether better outcomes could be achieved via targeted therapies. To do this, investigators chose to examine acalabrutinib—which demonstrated more selectivity and appeared more safe/efficacious with rituximab and CHOP (R-CHOP)—and tafasitamab—which has been successfully combined with lenalidomide and yields high ORRs and CR rates in…
Complete Interim Response, SCT Beats CAR T
Patients with relapsed diffuse large B cell lymphoma (DLBCL) who achieve a complete remission from interim chemotherapy while awaiting secondary chimeric antigen receptor (CAR) T cell therapy show significantly better outcomes if they then receive conventional autologous stem cell transplantation (auto-HCT), compared with CAR T therapy. “In patients with relapsed…
CRS Occurs in More Than Half of CAR-T Therapy Recipients
Real-world data suggested that cytokine release syndrome (CRS) among chimeric antigen receptor (CAR) T-cell therapy recipients with hematologic malignancy occurred among 56.2% to 71.7% of patients, according to results of a study that were presented at the ASH Annual Meeting 2023. “CRS is a potentially life threatening and supraphysiological response…
Tafasitamab Quadruplet Shows Efficacy in Newly Diagnosed DLBCL
Jason Westin, MD, MS, FACP The use of tafasitamab-cxix (Monjuvi), lenalidomide (Revlimid), rituximab (Rituxan), and acalabrutinib (Calquence; LTRA) in the first-line setting induced high responses in patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL), with responders deriving benefit from subsequent treatment with cyclophosphamide, doxorubicin, vincristine, and prednisolone (CHOP), according…
Multicenter Study at Sylvester, Other Academic Centers Shows CAR-T Cell Therapy Safe, Effective Even for High-Risk Patients
“CAR-T has caused a paradigm shift in the treatment of patients with diffuse large B-cell lymphoma,” said Jay Y. Spiegel, MD, hematologist-oncologist at Sylvester Comprehensive Cancer Center and the study’s lead presenter at ASH. “Our findings support the vast potential of this therapy, even for high-risk patients, but highlight the…
NX-1607 Is Under Phase 1 Evaluation in DLBCL and Other Advanced Malignancies
NX-1607 in DLBCL | Image Credit: © freshidea – stock.adobe.com The phase 1a/1b NX-1607-101 trial (NCT05107674) will evaluate NX-1607, a CBL-B inhibitor, in patients with advanced malignancies, including diffuse large B-cell lymphoma (DLBCL), according to a poster that was presented during the 2023 ASH Annual Meeting. The dose-escalation portion of…
Nurix Therapeutics Presents Positive Clinical Data from Its Novel Bruton’s Tyrosine Kinase (BTK) Degrader Programs, NX-5948 and NX-2127, at the 65th American Society of Hematology (ASH) Annual Meeting | Vaccines
Nurix Therapeutics Presents Positive Clinical Data from Its Novel Bruton’s Tyrosine Kinase (BTK) Degrader Programs, NX-5948 and NX-2127, at the 65th American Society of Hematology (ASH) Annual Meeting Details Category: Vaccines Published on Tuesday, 12 December 2023 14:30 Hits: 227 Positive preliminary efficacy data with a favorable safety profile support…
CAR-T Cell Therapy Revolutionizes DLBCL Treatment
Groundbreaking advancements in the field of medical science have given rise to a new era in the treatment of Diffuse Large B-Cell Lymphoma (DLBCL). One such major development is the introduction of chimeric antigen receptor T (CAR-T) cell therapy, a form of immunotherapy that has shown promising results in treating…
Recent Developments in Lymphoma Treatment
Combination Therapy Shows Promising Results In a recent Phase 1/2 trial, a combination of mosunetuzumab, a CD20-CD3 bispecific antibody, and polatuzumab vedotin, an anti-CD79B antibody-drug conjugate, demonstrated a significant overall response rate of 59.2% in patients with relapsed or refractory large B Cell lymphoma. This study, presented at the ASH23…
Research Unlocks Prediction Potential for Incurable Cancer Progression
Researchers have come one step closer to answering why, in some patients, a type of lymphoma changes from indolent to aggressive, and in particular they are closer to identifying which patients are at high risk of this change happening. Part of the answer lies in the protein expression in the…
Caribou Biosciences Provides Regulatory Update on CB-010 Pivotal Plan with Phase 3 Trial Initiation Expected by YE 2024
Caribou Biosciences, Inc. — Caribou met with the FDA and reached alignment on a pivotal trial in 2L LBCL with CB-010 versus a comparator arm of immunochemotherapy followed by HDCT and ASCT — — ANTLER Phase 1 trial continues dose expansion enrollment; initial dose expansion data and RP2D expected Q2…
ADC Therapeutics Announces Initial Results from
Combination demonstrated clinically meaningful benefit in r/r FL patients with 96% overall response rate and 85% complete response rate LAUSANNE, Switzerland, Dec. 12, 2023 (GLOBE NEWSWIRE) — ADC Therapeutics SA (NYSE: ADCT) today announced initial results from an investigator-initiated Phase 2 clinical trial evaluating ZYNLONTA® (loncastuximab tesirine-lpyl) in combination with…
CAR-T Cell Therapy is Safe, Effective in DLBCL, Including High-Risk Patients
Study results demonstrate that CAR-T cell therapy—a type of immunotherapy that genetically reengineers T cells to help the immune system find and kill cancerous cells—is a safe and effective treatment for diffuse large B-cell lymphoma (DLBCL). In addition, this therapy was found safe in patients who are considered high risk…
Caribou Biosciences Provides Regulatory Update on CB-010
— Caribou met with the FDA and reached alignment on a pivotal trial in 2L LBCL with CB-010 versus a comparator arm of immunochemotherapy followed by HDCT and ASCT — — ANTLER Phase 1 trial continues dose expansion enrollment; initial dose expansion data and RP2D expected Q2 2024 — —…
The future of lymphoma treatment
In the current landscape of drug discovery, lymphoma poses a significant challenge and opportunity. Researchers are fervently exploring novel therapeutic avenues, such as Antibody-Drug Conjugates (ADCs), to address the complexities of lymphoma. ARC-02, a standout candidate, demonstrates enhanced efficacy and tolerability in lymphoma treatment. While eyeing a diverse ADC pipeline,…
Diffuse Large B-cell Lymphoma Therapeutics Market Size, Share, Value and Report 2023-2030
The forecasted growth in the treatment of Diffuse Large B-cell Lymphoma (DLBCL) is driven by the increasing preference for targeted therapies. Targeted therapies, such as monoclonal antibodies and kinase inhibitors, offer a less toxic alternative to chemotherapy by focusing on specific molecular targets associated with cancer. Notable examples include rituximab…
Collaborative study shows CAR-T cell therapy safe, effective even for high-risk patients
Credit: Pixabay/CC0 Public Domain CAR-T cell therapy is a safe and effective treatment for diffuse large B-cell lymphoma (DLBCL), even for patients regarded as high risk due to comorbidities. That’s the conclusion of a five-year analysis of results from the U.S. Lymphoma CAR-T Cell Consortium, a group of 17 academic…
Integrating CAR-T cell therapy into the management of DLBCL: what we are learning
Introduction: Chimeric Antigen Receptor ;(CAR) T cells therapies have become part of the standard of care for patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL). The weakness of CAR-T therapies is that there are no comparative clinical trials, although many publications based on real-life data have confirmed the results…
Primary Thyroid Lymphoma: Clinical Factors Predicting the Possibility of Diffuse Large B-Cell Lymphoma
Aims: Among primary thyroid lymphomas (PTLs), diffuse large B-cell lymphoma (DLBCL) has a poorer prognosis than other indolent lymphomas such as mucosa-associated lymphoid tissue (MALT) or follicular lymphoma (FL). However, the clinical differences between DLBCL and indolent lymphoma remain unclear. Therefore, this retrospective study on PTL was aimed at investigating…
Regeneron announces new, updated data for odronextamabn in R/R DLBCL
Regeneron Pharmaceuticals announced new and updated data for odronextamab in patients with relapsed/refractory diffuse large B-cell lymphoma, or DLBCL. The data from the pivotal Phase 2 trial and Phase 1 trial were shared in several presentations – including two orals – at the 65th American Society of Hematology Annual Meeting…
Marker Therapeutics (MRKR) Announces Sustained Complete Response in First Lymphoma Patient Treated with MT-601 following CAR T Relapse
Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today reported a clinical update on the APOLLO study. The Phase 1 APOLLO study is investigating MT-601, a multi-tumor associated antigen (multiTAA)-specific T cell…
Latest Odronextamab Data in Relapsed/Refractory Follicular Lymphoma Showed Compelling Responses and Overall Maintenance of Patient-Reported Outcomes | Antibodies
Latest Odronextamab Data in Relapsed/Refractory Follicular Lymphoma Showed Compelling Responses and Overall Maintenance of Patient-Reported Outcomes Details Category: Antibodies Published on Monday, 11 December 2023 10:18 Hits: 243 Updated results presented at ASH demonstrated an 80% objective response rate and a 73% complete response (CR), with a 23-month median duration…
Regeneron Presents Positive Phase II Results for its Lymphoma Drug
Pictured: Regeneron logo on a light brown building/Shutterstock, Lev Radin Regeneron has lifted the curtain on Phase II data for odronextamab, which it is investigating in patients with relapsed/refractory follicular lymphoma. Regeneron’s investigational CD20xCD3 bispecific antibody results were announced Sunday at the American Society of Hematology annual meeting. Regeneron said…
Odronextamab Shows “Encouraging” Activity in Relapsed/Refractory DLBCL
Odronextamab has demonstrated efficacy in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), according to research presented at the ASH Annual Meeting 2023. Final results from the ELM-2 trial confirmed the “encouraging” clinical activity of odronextamab in these heavily pretreated patients, said study presenter Sabarish Ayyappan, MD, of…
Racial, ethnic disparities in mortality risk shown among younger patients with DLBCL
December 11, 2023 3 min read Add topic to email alerts Receive an email when new articles are posted on Please provide your email address to receive an email when new articles are posted on . ” data-action=subscribe> Subscribe We were unable to process your request. Please try again later….
Relapsed DLBCL: With Complete Interim Response, SCT Outperforms CAR T
Patients with relapsed diffuse large B cell lymphoma (DLBCL) who achieve a complete remission from interim chemotherapy while awaiting secondary chimeric antigen receptor (CAR) T cell therapy show significantly better outcomes if they then receive conventional autologous stem cell transplantation (auto-HCT), compared with CAR T therapy. “In patients with relapsed…
DLBCL arising from indolent lymphomas: How are they different?
. 2023 Nov 23:S0037-1963(23)00089-6. doi: 10.1053/j.seminhematol.2023.11.002. Online ahead of print. Affiliations Expand Affiliations 1 Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA; Harvard Medical School, Boston, MA; Broad Institute of MIT and Harvard, Cambridge, MA. 2 Aix-Marseille University, CNRS, INSERM, Centre d’Immunologie de Marseille-Luminy, Marseille, France. 3 Centre for…
Genentech: Press Releases | Sunday, Dec 10, 2023
Sunday, Dec 10, 2023 New Data for Genentech’s Columvi and Lunsumio Presented at ASH 2023 Support Continued Benefit for People With Lymphoma Longer-term data from pivotal studies of fixed-duration Columvi and Lunsumio continue to show durable responses in people with heavily pre-treated lymphomas New data reinforce the potential of…
New Data for Genentech’s Columvi and Lunsumio Presented at ASH 2023 Support Continued Benefit for People With Lymphoma
– Longer-term data from pivotal studies of fixed-duration Columvi and Lunsumio continue to show durable responses in people with heavily pre-treated lymphomas – – New data reinforce the potential of combination regimens in earlier treatment settings and add to the robust body of evidence supporting ongoing Phase III studies –…
New data for Roche’s Columvi and Lunsumio presented at ASH
Longer-term data from pivotal studies of fixed-duration Columvi and Lunsumio continue to show durable responses in people with heavily pre-treated lymphomas1,2 New data reinforce the potential of combination regimens in earlier treatment settings and add to the robust body of evidence supporting ongoing Phase III studies3,4,5,6 Basel, 11 December 2023…
MorphoSys Says Pelebresib-Ruxolitinib Combination Reduced Spleen Size, Symptoms in Phase 3 Trial in Myelofibrosis Patients -December 11, 2023 at 04:13 am EST
MorphoSys AG is a global commercial-stage biopharmaceutical company based in Germany. The Company discovers, develops, and delivers cancer medicines to patients. It markets its proprietary medicine Monjuvi (tafasitamab-cxix) in the United States, a cancer immunotherapy treatment, used to treat patients in combination with lenalidomide with second and later lines of…
Odronextamab Continues to Appear Safe, Effective in Patients With R/R DLBCL
Treatment with odronextamab (REGN1979) led to an objective response rate (ORR) of 52%, with encouraging progression-free (PFS) and overall survival (OS) among complete responders in a cohort of patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL), according to a final analysis of the phase 2 ELM-2 trial (NCT03888105) presented at…
Pilot study uses circulating tumor DNA to reliably predict relapse in patients with diffuse large B-cell lymphoma (DLBCL)
MAESTRO-Pool, a means of detecting circulating tumor DNA (ctDNA), could be sensitive and selective enough to help guide treatment decisions. Dana-Farber Cancer Institute investigators, in collaboration with researchers from the Broad Institute, demonstrated in a retrospective clinical study that a novel test for ctDNA was more sensitive and more specific…
Khan Discusses Third-Line Novel Treatment Approaches for R/R DLBCL
Cyrus M. Khan, MD (MODERATOR) Hematologist Division of Hematology and Cellular Therapy West Penn Hospital of Allegheny Health Network Pittsburgh, PA EVENT REGION Pennsylvania PARTICIPANT LIST Haixia Qin, MD, PhD | Simi Rai, MD | Naeem Latif, MD | Alexander Barsouk, MD | Gurprataap Sanhu, MD | Hayman Salib, MD…
Frontline Therapy Intensity, Outcomes Are Age-Specific in Elderly With DLBCL
Frontline treatment of older patients with diffuse large B-cell lymphoma (DLBCL) with standard dose R-CHOP was associated with improved real-world progression-free survival (rwPFS) and real-world overall survival (rwOS) compared with reduced dose R-CHOP and nonanthracycline regimens, but only in patients aged 70 to 79 years. In patients 80 years and…
Updated Odronextamab Data from Relapsed/Refractory Diffuse
Phase 2 primary analysis results presented in ASH oral session demonstrated a 52% objective response rate (ORR), with 31% achieving a complete response (CR) Results from a Phase 1 expansion cohort showed a 48% ORR and 30% CR in patients who had progressed on CAR-T Additional exploratory data from the…
Lower Relapse Rates Suggest Limited Value for Prophylaxis in DLBCL
SAN ANTONIO—Up to 40% of patients with diffuse large B-cell lymphoma (DLBCL) relapse or progress following first-line chemoimmunotherapy. Given the high rate of relapse, identifying the characteristics and outcomes associated with veterans with DLBCL who relapse could enable better monitoring or quicker intervention and potentially extend survival. In an effort…
Older DLBCL Patients Overestimate Chance for Cure, Survey Says
A new survey shows that older adults with aggressive non-Hodgkin lymphoma tend to overestimate their chance for a cure, highlighting a need for better patient education. Results were presented at the 65th ASH Annual Meeting and Exposition by Netana Markovitz, MD, of Beth Israel Deaconess Medical Center in Boston, and…
Scenic Biotech Announces Positive Preclinical Data for its QPCTL Inhibitor SC-2882 as Potential New Therapeutic Approach for Diffuse Large B-Cell Lymphoma
SC-2882 shows anti-lymphoma and anti-immunosuppression effect in a mouse model for diffuse large B-Cell lymphoma Data presented today, December 9, at the 65th ASH Annual Meeting & Exposition in San Diego, CA, by Leandro Cerchietti, MD, Richard A. Stratton Associate Professor in Hematology and Oncology at Weill Cornell Medicine, New…
Selinexor Combined With BTK Inhibitors Effective in DLBCL and PCNSL Care
SAN DIEGO, California—The combination of selinexor, an Exportin-1 (nuclear output protein XPO1) inhibitor, and Bruton tyrosine kinase inhibitors (BTKi) can inhibit tumor signaling pathways in diffuse large B-cell lymphoma (DLBCL) and primary central nervous system lymphoma (PCNSL), according to a poster presented at the 65th American Society of Hematology Annual…
Women With Excessive Visceral Fat May Be at Risk for DLBCL Progression
Women with diffuse large B cell lymphoma (DLBCL) and visceral fat above the tolerable range could have a worse prognosis, according to a recently published study in the European Journal of Radiology. DLBCL is characterized by a torpid disease course. Although R-CHOP chemotherapy has been associated with improved survival rates,…
B-Cell Lymphomas Pipeline, FDA Approvals, Clinical Trials Developments and Companies 2023
PRESS RELEASE Published December 7, 2023 DelveInsight’s, “B-Cell Lymphoma Pipeline Insight 2023” report provides comprehensive insights about 160+ companies and 170+ pipeline drugs in B-Cell Lymphoma pipeline landscape. It covers the B-Cell Lymphomas pipeline drug profiles, including clinical and nonclinical stage products. It also covers the B-Cell Lymphomas pipeline therapeutics…
CAR T Cell Therapy May Be Effective but Unaffordable as Second Line Therapy for Patients With DLBCL
By The ASCO Post StaffPosted: 12/6/2023 9:39:00 AM Last Updated: 12/6/2023 10:33:56 AM Investigators have found that chimeric antigen receptor (CAR) T-cell therapy may be an effective but unaffordable second-line treatment option for patients with relapsed diffuse large B-cell lymphoma (DLBCL), according to a recent study published by Kelkar et al…
Discussing Subgroup Responses to Immunotherapy and R-CHOP in DLBCL
CASE A 58-year-old retired schoolteacher presented with the chief complaint of swollen lymph nodes in his neck and groin, persistent fatigue, night sweats, and unintentional weight loss of 15 pounds over the last 2 months. Social/family history: married, lives in rural area, grandfather, grown children live in state, works occasionally as a substitute teacher,…
Real-world treatment patterns, survival, health resource use and costs among Medicare beneficiaries with diffuse large B-cell lymphoma
doi: 10.2217/fon-2023-0191. Online ahead of print. Affiliations Expand Affiliations 1 Merck & Co., Inc., Rahway, NJ 07065, USA. 2 COVIA Health Solutions, Lansdale, PA 19446, USA. 3 Division of General Internal Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA. 4 Department of Internal Medicine, Section of Hematology, Yale University…
Diffuse Large B-Cell Lymphoma (DLBCL) Treatment Market Key Business Opportunities, Impressive Growth Rate and Analysis to 2030 | by Vikashundekar | Dec, 2023
The report furnishes a comprehensive analysis of the Global Diffuse Large B-Cell Lymphoma (DLBCL) Treatment Market for 2023, encompassing global, regional, and country-specific dimensions. It covers various aspects, including market sizes, segmentation market growth, competitive landscape, market share, sales analysis, and the influence of both domestic and global players in…
Cost-Effectiveness and Health Care Spending
Chimeric antigen receptor T-cell (CAR-T) therapies, such as axicabtagene ciloleucel (axi-cel) and lisocabtagene maraleucel (liso-cel), have been hailed as breakthroughs in the treatment of various cancers. However, a recent study published in the Annals of Internal Medicine has raised questions about their cost-effectiveness for patients with diffuse large B-cell lymphoma…
8-year-old in hospice wants 2,000 cards for Christmas: How to help
If you’re looking to give some love this holiday season, there is a young boy who would appreciate getting a Christmas or birthday card from you. Andrew Miller is an 8-year-old who enjoys cards and loves reading them every day. He was diagnosed with two types of Stage 4 cancers last year….
What are the prognostic factors for diffuse large B-cell lymphoma?
What are the factor of prognosis of pneumonia?4 answersThe factors associated with the prognosis of pneumonia include cytokine levels such as interleukin-6 (IL-6), interferon-γ (IFN-γ), granulocyte colony-stimulating factor (G-CSF), monocyte colony-stimulating factor (M-CSF), monocyte chemoattractant protein-1 (MCP-1), monocyte chemoattractant protein-3, Interleukin-2 receptor subunit alpha, and Hepatocyte growth factor. Other biomarkers…
Real-World Treatment Patterns, Survival, Health Resource Use, and Costs among Medicare Beneficiaries with DLBCL
Supplement S1. ICD-9 and ICD-10 Codes for DLBCL Supplement S2. List of individual agents used for DLBCL Supplement S3. Classifying Lines of Therapy Supplement S4. Note on Classification Hierarchy Supplement S5. Codes for Identifying Stem Cell Transplant Supplement S6. Sample attrition Supplement S7. Treatment regimens Supplement S8. All-Cause and DLBCL-related*…
Nanochip Technology in Monitoring Treatment Response and Detecting Relapse in Participants With Diffuse Large B-Cell Lymphoma
PRIMARY OBJECTIVES: I. Determine whether ILN biochip can be used to detect molecular marker(s) to monitor treatment response in patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL). II. Determine whether ILN biochip can promote early detection of disease relapse in patients with DLBCL. OUTLINE: Participants’ blood samples undergo ILN…
Hybrid Friday Satellite Symposium on R/R DLBCL | Preceding the 65th ASH Annual Meeting & Exposition Tickets, Fri, Dec 8, 2023 at 3:00 PM
Hybrid Friday Satellite Symposium on R/R DLBCL | Preceding the 65th ASH Annual Meeting & Exposition Attend In-Person or Virtually for an exciting and informative event, Advances in Precision Medicine for Relapsed/Refractory Diffuse Large B-Cell Lymphoma Care, happening at the San Diego Convention Center on Friday, December 8, 2023, 3:00…
Tafasitamab Effective in Combination Therapy for Untreated DLBCL
A phase 1b study demonstrated the feasibility of using first-line tafasitamab with R-CHOP plus or minus lenalidomide in patients with previously untreated diffuse large B-cell lymphoma (DLBCL). Study results were reported in the journal Blood. The open-label phase 1b First-MIND study (ClinicalTrials.gov Identifier: NCT04134936) enrolled patients with previously untreated DLBCL…
Study Finds Axicabtagene Ciloleucel and Lisocabtagene Maraleucel Not Cost-Effective
MONDAY, Dec. 4, 2023 (HealthDay News) — For patients with diffuse large B-cell lymphoma (DLBCL), the chimeric antigen receptor T-cell therapies (CAR-T) axicabtagene ciloleucel (axi-cel) and lisocabtagene maraleucel (liso-cel) are not cost-effective, according to a study published online Dec. 5 in the Annals of Internal Medicine. Amar H. Kelkar, M.D.,…
CTL019 Out of Specification MAP for ALL or DLBCL Patients
Managed Access Program (MAP) to provide access to CTL019, for acute lymphoblastic leukemia (ALL) or diffuse large b-cell lymphoma (DLBCL) patients with out of specification leukapheresis product and/or manufactured tisagenlecleucel out of specification for commercial release. Stanford is currently accepting patients for this trial. Eligibility Inclusion Criteria: Patients eligible for…
Noncoding mutations cause super-enhancer retargeting resulting in protein synthesis dysregulation during B cell lymphoma progression
B cells undergo a series of programmed genomic alterations that enable the immunoglobulin light and heavy chain loci to generate high-affinity antibodies against invading pathogens. First, B cells undergo variability, diversity and joining (VDJ) recombination in the bone marrow with subsequent somatic hypermutation (SHM) and class switch recombination (CSR) occurring…
Diffuse Large B-cell Lymphoma Market to Observe Impressive Growth Ubix Therapeutics, Otsuka Pharmaceutical, Biomea Fusion, Autolus Limited, Xynomic Pharmaceuticals companies are expected to change the Market scenario by 2032, forecasts DelveInsight.
DelveInsight’s “Diffuse Large B-cell Lymphoma Market Insights, Epidemiology and Market Forecast– 2032” report delivers an in-depth understanding of the DLBCL, historical and forecasted epidemiology as well as the DLBCL market trends in the United States, EU4 (Germany, Spain, Italy, and France), the United Kingdom, and Japan. {Delhi, India} To strategically…
Resistance to Targeted Agents Used to Treat Paediatric ALK-Positive ALCL
Popis Simple Summary In general, the non-Hodgkin lymphoma (NHL), anaplastic large cell lymphoma (ALCL) diagnosed in childhood has a good survival outcome when treated with multi-agent chemotherapy. However, side effects of treatment are common, and outcomes are poorer after relapse, which occurs in up to 30% of…
In vitro cytotoxicity of ranpirnase (onconase) in combination with components of R-CHOP regimen against diffuse large B cell lymphoma (DLBCL) cell line
Abstract Ranpirnase (onconase; ONC) is an endoribonuclease obtained from the frog Rana pipiens. This enzyme exhibits anticancer properties mediated by degradation of cellular RNA and induction of apoptosis. In this study we assessed cytotoxicity of ONC in combination with currently used anticancer drugs on a human diffuse large B-cell lymphoma…
Seattle Genetics Inc. Announces Encouraging Data from Phase II DLBCL Trials -January 01, 2015 at 01:08 am EST
Seattle Genetics Inc. announced encouraging data from Phase II clinical trials for ADCETRIS in patients with relapsed/refractory and frontline diffuse large B-cell lymphoma, or DLBCL. ADCETRIS is an antibody-drug conjugate (ADC) directed to CD30, which is expressed in classical Hodgkin lymphoma, anaplastic large cell lymphoma and several other types of…
Ny tantaran’i Kim – DLBCL & CAR T-cell therapy
Tamin’ny Septambra 2020, i Kim dia voan’ny Lymphoma B-Cell Diffuse Large. Indrisy anefa fa tsy namaly ny fitsaboana tamin’ny voalohany i Kim. Ny ekipany ao amin’ny Hopitaly PA any Brisbane dia afaka nanondro azy ho any amin’ny ekipa mpitrandraka ao amin’ny RBWH mba hidirana amin’ny fitsaboana T-cell CAR vaovao. Hatramin’ny…
Timing of DLBCL Relapse Linked With Evolutionary Patterns
Patients with diffuse large B-cell lymphoma (DLBCL) categorized as having late relapses, defined as those who relapse more than 2 years after their initial diagnosis, often have genetically distinct and chemotherapy-naive disease compared with patients with early relapses, according to findings published in the Journal of Clinical Oncology.1 Investigators noted…